Shire accepts €52.4bn takeover bid by Takeda
Following weeks of negotiations and four rejected bids, British neurology and orphan drug giant Shire has agreed to Takeda’s latest take-over offer of £46bn (€52,38bn).
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2128 entries already.
Entries by Thomas Gabrielczyk
Narasimhan embraces Swiss biotech industry
Vas Narasimhan, the newly appointed CEO of Swiss pharma giant Novartis, introduced himself to the Swiss biotech industry with a stimulant talk at the Swiss Biotech Day. Apart from that participants of the annual gathering were in high spirits as the Swiss biotech sector continues to grow steadily.
Partnership drives connectivity in injectible meds
Swiss injection pen developer Haselmeier and Boston-based Common Sensing have partnered to develop smart connected self-injection devices that can monitor drug administration, dosing and efficacy of therapies.
Go Jelly, go
The UK-based pioneer in marine biotechnologies Jellagen has closed a £3.8m funding round to boost sales of its next-generation jellyfish-based medicine. Lead investor were Newable Private Investing and the Development Bank of Wales.
Irish Iterum files for IPO on Nasdaq
Iterum Therapeutics plans to raise up to US$92m in an initial public offering on US technology stock market Nasdaq. The Irish company develops oral and IV antibiotics for urinary tract infections and intra-abdominal infections.
Near-term capital for Neurimmune
US biotech company Biogen has exercised the option of a one-off payment to Swiss developer Neurimmune. If Biogen’s Alzheimer’s candidate Aducanumab is approved, the sales-related payments to Neurimmune will thus be reduced by 5%.
Diabetes drug reverses PAH
A new study shows that a drug approved for the treatment of diabetes reverses pulmonary arterial hypertension (PAH) and prevents right heart failure in rats. Ekaterina Legchenko and colleagues say their findings could lead to new therapies for PAH and other chronic heart and lung conditions.
Targovax gives pipeline update
Norwegian Targovax ASA has given an update of its immunononcology and pancreatic cancer clinical pipeline at ChinaBio Conference in Suzhou.
Inhibitor-free DNA for increased reliability in PCR analysis
BioEcho GmbH develops kits for the isolation and processing of DNA and RNA with a rapidly expanding portfolio. With expertise and passion, we overcome the limitations of common nucleic acid extraction with pioneering methods such as the proprietary Echolution single-step technology.
AZ’s Durvalumab/Tremelimumab combo flops in NSCLC
British drug maker AstraZeneca has failed to expand the reach of its combo of PD-1/CTLA4 checkpoint blockers Durvalumab/Tremelimumab. The approved second-line NSCLC treatment missed to prolong progression-free and overall survival in patients with low PD-L1 expression.